Combined pharmacotherapies and behavioral interventions for alcohol dependence (The COMBINE Study): examination of posttreatment drinking outcomes - PubMed (original) (raw)

Randomized Controlled Trial

Combined pharmacotherapies and behavioral interventions for alcohol dependence (The COMBINE Study): examination of posttreatment drinking outcomes

Dennis M Donovan et al. J Stud Alcohol Drugs. 2008 Jan.

Abstract

Objective: The aim of this study was to examine the efficacy of pharmacological and behavioral interventions across 1 year posttreatment in the COMBINE (Combining Medications and Behavioral Interventions) Study.

Method: Alcohol-dependent individuals (N = 1,383; 428 women) recruited at 11 outpatient academic alcoholism-treatment clinics across the United States participated in a randomized, double-blind, placebo-controlled trial. They received 16 weeks of naltrexone (Revia) or acamprosate (Campral) or both medications and/or placebos in combination with medical management (MM), with or without combined behavioral intervention (CBI); one group received CBI without pills or MM. Drinking behavior and clinical status were assessed at the end of treatment (Week 16) and at Weeks 26, 52, and 68.

Results: Prior treatment with active naltrexone, without active acamprosate or CBI or with active acamprosate plus CBI, and CBI with double placebo resulted in a significantly higher percentage of days abstinent than double placebos with no CBI (p < .05). Having received CBI was associated with positive clinical response posttreatment, compared with not having received CBI. Prior treatment with naltrexone increased the time to the first heavy-drinking day posttreatment (p = .03). No differences were found between patients who had received CBI without MM or pills and those having received MM and double placebo with or without CBI. No significant main effects for acamprosate were found on any of the outcome measures.

Conclusions: Previous treatment with MM and either CBI or naltrexone, or both, but not acamprosate, was associated with sustained efficacy beyond discontinuation. Reasons for the maintained treatment gains with naltrexone and/or CBI and potential methods to extend them are discussed.

PubMed Disclaimer

Cited by

Readiness to Provide Medications for Addiction Treatment in HIV Clinics: A Multisite Mixed-Methods Formative Evaluation.
Edelman EJ, Gan G, Dziura J, Esserman D, Morford KL, Porter E, Chan PA, Cornman DH, Oldfield BJ, Yager JE, Muvvala SB, Fiellin DA. Edelman EJ, et al. J Acquir Immune Defic Syndr. 2021 Jul 1;87(3):959-970. doi: 10.1097/QAI.0000000000002666. J Acquir Immune Defic Syndr. 2021. PMID: 33675619 Free PMC article.
Social support and depressive symptoms: exploring stigma and self-efficacy in a moderated mediation model.
Wang DF, Zhou YN, Liu YH, Hao YZ, Zhang JH, Liu TQ, Ma YJ. Wang DF, et al. BMC Psychiatry. 2022 Feb 15;22(1):117. doi: 10.1186/s12888-022-03740-6. BMC Psychiatry. 2022. PMID: 35168584 Free PMC article.
Acamprosate and naltrexone treatment effects on ethanol and sucrose seeking and intake in ethanol-dependent and nondependent rats.
Czachowski CL, Delory MJ. Czachowski CL, et al. Psychopharmacology (Berl). 2009 Jun;204(2):335-48. doi: 10.1007/s00213-009-1465-z. Epub 2009 Jan 20. Psychopharmacology (Berl). 2009. PMID: 19153715 Free PMC article.
Practical outpatient pharmacotherapy for alcohol use disorder.
Kim Y, Hack LM, Ahn ES, Kim J. Kim Y, et al. Drugs Context. 2018 Feb 7;7:212308. doi: 10.7573/dic.212308. eCollection 2018. Drugs Context. 2018. PMID: 29445407 Free PMC article. Review.
Integrated treatment of substance use and psychiatric disorders.
Kelly TM, Daley DC. Kelly TM, et al. Soc Work Public Health. 2013;28(3-4):388-406. doi: 10.1080/19371918.2013.774673. Soc Work Public Health. 2013. PMID: 23731427 Free PMC article. Review.

Combined pharmacotherapies and behavioral interventions for alcohol dependence (The COMBINE Study): examination of posttreatment drinking outcomes - PubMed (original) (raw)